Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drug study reveals hidden genetic links to weight and inflammation

NCT ID NCT07120828

Disease control Sponsor: Erbil Polytechnic University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at how two common diabetes drugs, dapagliflozin and empagliflozin, affect weight, cholesterol, and inflammation in 260 obese adults newly diagnosed with type 2 diabetes. Over six months, researchers measured changes in body weight, blood fats, and markers of oxidative stress, and also checked how a gene called CYP8B1 might influence these effects. The goal was to better understand the broader health benefits of these medications beyond blood sugar control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

260 people

The number who actually took part.

Started

Jul 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed with Type 2 Diabetes Mellitus (within the past 6 months). * Body Mass Index (BMI) ≥ 30 kg/m² (classified as obese). * No prior treatment with SGLT2 inhibitors or other antidiabetic medications. * Willing and able to provide written informed consent. * Able to comply with study visits, procedures, and sample collection. Exclusion Criteria: * History or diagnosis of Type 1 diabetes mellitus or secondary forms of diabetes. * Estimated Glomerular Filtration Rate (eGFR) \< 45 mL/min/1.73 m² (moderate to severe renal impairment). * Active liver disease or significant hepatic dysfunction. * Current pregnancy or breastfeeding. * Known hypersensitivity or contraindication to SGLT2 inhibitors. * hypertension * Any other condition that, in the opinion of the investigator, may interfere with the patient's ability to complete the study or pose additional risk.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obese diabetics are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obese diabetics Obese patients (bmi ≥ 30 KG/m²) Type 2 diabetes

Contacts and locations

Locations

  • Epu

    Erbil, Kurdistan, 44001, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.